Baxter bids $3,800 million for WR Grace's renal business
This article was originally published in Clinica
Executive Summary
Baxter has offered $3,800 million in cash and stock to take over WR Grace's dialysis subsidiary National Medical Care (NMC). Baxter made its offer on January 31st in a letter to Grace's CEO, Albert Costello, with a request to respond within 24 hours. However, Grace has not indicated any willingness to enter into discussions, Baxter said when it went public with the offer on February 2nd. At the time Clinica went to press, no comment from Grace was available.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.